{"id":501094,"date":"2020-08-07T20:02:01","date_gmt":"2020-08-07T20:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=501094"},"modified":"2020-08-07T20:02:01","modified_gmt":"2020-08-07T20:02:01","slug":"tim3next-generation-immunotherapy-competitive-landscape-and-market-forecast-2035","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/tim3next-generation-immunotherapy-competitive-landscape-and-market-forecast-2035_501094.html","title":{"rendered":"TIM-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"TIM-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"TIM-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018TIM-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035\u2019 report delivers an in-depth understanding of the TIM-3 as well as the market trends of TIM-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/div>\n<ul style=\"text-align: justify;\">\n<li>Cancer Immunotherapy involves antibodies to inhibit immune checkpoint molecules. Fighting cancer with immunotherapy has revolutionized treatment for some patients and therapies targeting the immune checkpoint molecules such as CTLA-4 and PD-1 in melanoma, renal cancer, Hodgkin&rsquo;s diseases and lung cancer.<\/li>\n<li>TIM-3 is a co-inhibitory receptor that is expressed on IFN-&gamma;-producing T cells, FoxP3+ Treg cells and innate immune cells (macrophages and dendritic cells) where it has been shown to suppress their responses upon interaction with their ligand(s).<\/li>\n<li>TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that in vivo blockade of TIM-3 with other check-point inhibitors enhances anti-tumor immunity and suppresses tumor growth in several preclinical tumor models.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/TIM-3-next-generation-immunotherapy-competitive-landscape\" target=\"_blank\"><strong>TIM-3-Next Generation Immunotherapy Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;TIM-3-Next Generation Immunotherapy Market is anticipated to be USD 1,218 Million in the year 2035<\/p>\n<p style=\"text-align: justify;\">Market Driver- Launch of potential upcoming therapies<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/TIM-3-next-generation-immunotherapy-competitive-landscape\" target=\"_blank\"><strong>TIM-3-Next Generation Immunotherapy Pipeline<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/TIM-3-next-generation-immunotherapy-competitive-landscape\" target=\"_blank\"><strong>Emerging Therapies<\/strong><\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>TSR-022<\/strong><\/li>\n<li><strong>MBG453<\/strong><\/li>\n<li><strong>ONO-7807\/BMS-986258<\/strong><\/li>\n<li><strong>BGB-A425 +\/&ndash; Tislelizumab<\/strong><\/li>\n<li><strong>Sym023<\/strong><\/li>\n<li><strong>INCAGN2390<\/strong><\/li>\n<li><strong>RG7769\/RO7121661<\/strong><\/li>\n<li><strong>LY3321367<\/strong><\/li>\n<li><strong>Sym022 <\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others<\/p>\n<p style=\"text-align: justify;\"><strong>Key Players:-<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Symphogen<\/li>\n<li>GlaxoSmithKline<\/li>\n<li>Novartis<\/li>\n<li>Bristol-Myers Squibb<\/li>\n<li>Ono Pharmaceuticals<\/li>\n<li>BeiGene<\/li>\n<li>Incyte Biosciences<\/li>\n<li>Agenus<\/li>\n<li>Roche<\/li>\n<li>Eli Lilly<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/tim-3-next-generation-immunotherapy-competitive-landscape\" target=\"_blank\"><strong>Request for sample pages<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/tim-3-next-generation-immunotherapy-competitive-landscape\" target=\"_blank\"><strong>Table of contents<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intensity of TIM-3-Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">4. Market Competition of TIM-3-Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">5. Technological innovations in TIM-3-Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">6. Multivariate analysis of the key players in TIM-3-Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">7. TIM-3-Next Generation Immunotherapy Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">7.1. Market Share (%) Distribution of Next-Generation Immunotherapy in 2035<\/p>\n<p style=\"text-align: justify;\">8. Pipeline Therapeutics Analysis (Active Products)<\/p>\n<p style=\"text-align: justify;\">9. Overview: Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">9.1. Immune Checkpoint Inhibitors<\/p>\n<p style=\"text-align: justify;\">9.2. TIM-3<\/p>\n<p style=\"text-align: justify;\">10. Future Prospects and Challenges in TIM-3-Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">10.1. Current Clinical Challenges in Immunotherapies<\/p>\n<p style=\"text-align: justify;\">10.2. Future direction of improving response rates of Immunotherapy<\/p>\n<p style=\"text-align: justify;\">11. SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">12. Epidemiology and Forecasting Assumptions<\/p>\n<p style=\"text-align: justify;\">13. Emerging Drugs<\/p>\n<p style=\"text-align: justify;\">13.1. Target indications of TIM-3<\/p>\n<p style=\"text-align: justify;\">13.2. TSR-022: GlaxoSmithKline<\/p>\n<p style=\"text-align: justify;\">13.2.1. Drug Description<\/p>\n<p style=\"text-align: justify;\">13.2.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.2.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.2.4. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.3. MBG453: Novartis<\/p>\n<p style=\"text-align: justify;\">13.3.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.3.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.3.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.3.4. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.4. ONO-7807\/BMS-986258: Bristol-Myers Squibb\/ Ono Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">13.4.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.4.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.4.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.4.4. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.5. BGB-A425 +\/&ndash; Tislelizumab: BeiGene<\/p>\n<p style=\"text-align: justify;\">13.5.1. Drug Description<\/p>\n<p style=\"text-align: justify;\">13.5.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.5.3. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.6. INCAGN2390: Incyte Biosciences\/Agenus<\/p>\n<p style=\"text-align: justify;\">13.6.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.6.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.6.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.6.4. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.7. Sym023: Symphogen<\/p>\n<p style=\"text-align: justify;\">13.7.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.7.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.7.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.7.4. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.8. RG7769\/RO7121661: Roche<\/p>\n<p style=\"text-align: justify;\">13.8.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.8.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.8.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.8.4. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.9. LY3321367: Eli Lilly<\/p>\n<p style=\"text-align: justify;\">13.9.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.9.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.9.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.9.4. Product Profile<\/p>\n<p style=\"text-align: justify;\">13.10. Sym022: Symphogen<\/p>\n<p style=\"text-align: justify;\">13.10.1.&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.10.2.&nbsp;Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.10.3.&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.10.4.&nbsp;Product Profile<\/p>\n<p style=\"text-align: justify;\">14. Assessment by Indication<\/p>\n<p style=\"text-align: justify;\">15. Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">16. Assessment by Stage and Indication<\/p>\n<p style=\"text-align: justify;\">17. Assessment by stage and Route of Administration<\/p>\n<p style=\"text-align: justify;\">18. TIM-3-7 Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">18.1. Market Outlook in the 7MM<\/p>\n<p style=\"text-align: justify;\">18.1.1. Total Market size of TIM-3 in 7MM<\/p>\n<p style=\"text-align: justify;\">18.1.2. Market Size of TIM-3 by indication in 7MM<\/p>\n<p style=\"text-align: justify;\">19. Market Drivers<\/p>\n<p style=\"text-align: justify;\">20. Market Barriers<\/p>\n<p style=\"text-align: justify;\">21. Appendix<\/p>\n<p style=\"text-align: justify;\">21.1. Report Methodology<\/p>\n<p style=\"text-align: justify;\">22. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">23. Disclaimer<\/p>\n<p style=\"text-align: justify;\">24. About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=tim3next-generation-immunotherapy-competitive-landscape-and-market-forecast-2035\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=tim3next-generation-immunotherapy-competitive-landscape-and-market-forecast-2035\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018TIM-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035\u2019 report delivers an in-depth understanding of the TIM-3 as well as the market trends of TIM-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/tim3next-generation-immunotherapy-competitive-landscape-and-market-forecast-2035_501094.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-501094","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=501094"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501094\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=501094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=501094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=501094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}